Welcome to Cambridge's website

  • Cambridge is a successful and progressive healthcare company with an international focus.
  • With offices in Ireland and the UK Cambridge specialise in the development, global registration, marketing, sales and distribution of innovative and classic specialist secondary care pharmaceutical products. Our products, which we have in-licensed or purchased outright from world-class partner companies, provide benefit in high profile therapeutic areas including the Central Nervous System (CNS) and Oncology.
  • Cambridge's success has been as a result of its management team, which consists of dynamic individuals who have the skills, expertise and vision to build winning brands. Our board of directors includes some of the most respected and renowned professionals in the healthcare industry.
  • Our vision is to become a leading provider of specialist pharmaceuticals for secondary care physicians. We will achieve this by developing market leading brands from targeted acquisitions and internal product development.

About Cambridge

- Our goal is to build winning brands, increase revenues

and create substantial value for our partners

Mark Evans – CEO

- Founded in 1987, Cambridge is an independent and privately owned company. The current Board of Directors, who purchased the company outright in 1996, includes some of the most notable and distinguished figures within the healthcare arena.

- Cambridge has continued to demonstrate substantial sales growth, twice that of the industry average. This remarkable growth rate has been facilitated by our core competencies, which include our unrivalled focus on customer service, the strength of our specialist UK sales team, and the expertise of our marketing team.

- Cambridge's success has been as a result of sustained global expansion through partnerships and collaborations with world-class healthcare companies, as well as the execution of a focused business strategy and vision. In addition, we have a management team, which consists of dynamic individuals who have the skills, expertise and vision to build winning brands.

- Our vision is to become a leading provider of specialist pharmaceuticals for secondary care physicians. We will achieve this by developing market leading brands from targetted acquisitions and internal product development.

Therapeutic Areas

We provide an extremely high degree of support to healthcare professionals at a global level..

Cambridge' current product portfolio consists of 23 products in the following areas :

  • Central Nervous System (CNS)
  • Oncology
  • Specialist Niche Hospital Products

Therapeutic Areas

Our portfolio is made up of innovative products, and classic pharmaceuticals, which we have revitalised and are successfully marketing. We also have a range of exciting products in our pipeline, which are presented in more detail in the Product Pipeline section.

Business Development

Alliance is committed to continued growth via acquisition, in-licensing new opportunities and forming mutually beneficial business partnerships.   Our management experience across a wide range of  pharmaceutical brands and markets allows rapid assessment of opportunities.  At this stage in Alliance’s development we are willing to look at all therapeutic areas. Whilst we are focussed on prescription pharmaceuticals, we are also exploring opportunities in semi-ethicals and related medical devices.

Innovation in Specialist Pharmaceuticals

  • Cambridge Laboratories is a fast growing, dynamic and entrepreneurial pharmaceutical company with extensive product development and commercialisation expertise. Our focus is on specialist pharmaceuticals with core products in Oncology and diseases of the central nervous system (CNS).
  • We have a proven track record in the development, global registration, marketing, sales and distribution of both innovative and well established pharmaceutical products. This, combined with our strong product portfolio and our ability to forge lasting relationships with global partners, has helped us generate substantial sales growth over the past 10 years.
  • We are proud of our independence and entrepreneurial culture. Equally, our strong balance sheet and freedom from debt give us a solid foundation from which we continue to enhance our growth.
  • Our focus is very firmly on the future and the opportunity to augment further targeted product acquisitions with our own internal development pipeline, bringing to market products that will help us fulfil previously unmet patient needs.